Tacrolimus inhibits hepatic ferroptosis in diabetes by modulating SIRT7-dependent NRF2 activation
Background
Type 2 diabetes (T2DM) is a growing global health burden, frequently complicated by hepatic steatosis and progressive diabetic liver disease. This condition is characterized by inflammation, fibrosis, and hepatocellular injury, driven by chronic hyperglycemia and insulin resistance. Key pathological mechanisms include lipotoxicity, oxidative stress, and iron overload, which collectively exacerbate cellular damage. Recent research highlights ferroptosis, an iron-dependent cell death pathway driven by lipid peroxidation, as a critical contributor to diabetic liver disease. Hepatocytes are particularly vulnerable due to high polyunsaturated fatty acid (PUFA) content and substantial iron stores, making ferroptosis inhibition a promising therapeutic target.
Why It Matters
Tacrolimus could protect against diabetic liver disease by targeting ferroptosis, a novel mechanism highlighted by this study. Given that diabetic liver injury is a significant complication of T2DM, identifying agents that mitigate ferroptosis offers a promising therapeutic strategy. While Tacrolimus is primarily known as an immunosuppressant, this research suggests its potential repurposing or investigation for its hepatoprotective effects in metabolic disorders. Future clinical studies are warranted to assess the safety and efficacy of Tacrolimus in this context, potentially leading to new treatment protocols for patients with T2DM and hepatic complications. This opens avenues for exploring existing drugs for new indications, addressing critical unmet needs in diabetic liver disease management.